Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) started the day on December 09, 2021, with a price increase of 0.39% at $0.72. During the day, the stock rose to $0.7446 and sunk to $0.7115 before settling in for the price of $0.72 at the close. Taking a more long-term approach, ADMP posted a 52-week range of $0.47-$2.34.
Meanwhile, its Annual Earning per share during the time was 9.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -23.30%. This publicly-traded company’s shares outstanding now amounts to $148.89 million, simultaneously with a float of $147.30 million. The organization now has a market capitalization sitting at $114.56 million. At the time of writing, stock’s 50-day Moving Average stood at $0.9714, while the 200-day Moving Average is $0.9672.
It is quite necessary to find out the efficiency of the corporate organization, which has 116 number of employees on its payroll. It has generated 142,478 per worker during the last fiscal year. Meanwhile, its income per employee was -425,785. The stock had 11.13 Receivables turnover and 0.41 Total Asset turnover. For the Profitability, stocks gross margin was +9.58, operating margin was -176.43 and Pretax Margin of -301.38.
Adamis Pharmaceuticals Corporation (ADMP) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. According to the most recent insider trade that took place on Dec 01, this organization’s Chief Financial Officer sold 13,554 shares at the rate of 0.79, making the entire transaction reach 10,640 in total value, affecting insider ownership by 43,478. Preceding that transaction, on Dec 01, Company’s SVP and Chief Business Officer sold 50,757 for 0.79, making the whole transaction’s value amount to 39,844. This particular insider is now the holder of 258,765 in total.
Adamis Pharmaceuticals Corporation (ADMP) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/30/2020, the organization reported -$0.24 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.06) by -$0.18. This company achieved a net margin of -298.84 while generating a return on equity of -249.86. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
Adamis Pharmaceuticals Corporation’s EPS decrease for this current 12-month fiscal period is -23.30% and is forecasted to reach -0.16 in the upcoming year.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) Trading Performance Indicators
Let’s observe the current performance indicators for Adamis Pharmaceuticals Corporation (ADMP). It’s Quick Ratio in the last reported quarter now stands at 4.60. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.37.
In the same vein, ADMP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.40, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be -0.16 at the market close of one year from today.
Technical Analysis of Adamis Pharmaceuticals Corporation (ADMP)
If we take a close look at the recent performances of Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), its last 5-days Average volume was 1.35 million that shows plunge from its year to date volume of 9.82 million. During the previous 9 days, stock’s Stochastic %D was recorded 35.47% While, its Average True Range was 0.0563.
Raw Stochastic average of Adamis Pharmaceuticals Corporation (ADMP) in the period of the previous 100 days is set at 8.49%, which indicates a major fall in contrast to 23.76% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 64.13% that was higher than 55.41% volatility it exhibited in the past 100-days period.